Lucira Health (NASDAQ:LHDX) Trading Down 9.9%
Lucira Health (NASDAQ:LHDX) Trading Down 9.9%
Lucira Health, Inc. (NASDAQ:LHDX – Get Rating)'s stock price was down 9.9% during mid-day trading on Tuesday . The company traded as low as $0.20 and last traded at $0.23. Approximately 525,450 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 29,320,967 shares. The stock had previously closed at $0.25.
盧西拉健康公司（NASDAQ：LHDX-獲取評級）的股票價格在周二中間交易期間下降了 9.9％。該公司的交易價格低至 0.20 美元，最後交易價格為 0.23 美元。在中間交易期間，約 525,450 股股份轉手，較每日平均成交量 29,320,967 股下降了 98%。該股票以前已收盤 0.25 美元。
Lucira Health Price Performance
盧西拉健康價格性能
The company has a market capitalization of $9.03 million, a price-to-earnings ratio of -0.06 and a beta of 3.75. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.79 and a current ratio of 1.46. The business has a 50 day moving average price of $0.33 and a 200-day moving average price of $0.58.
該公司的市值為 903 萬美元，價格與收益比為 -0.06，測試版為 3.75。該公司的債務與權益比率為 0.48，快速比率為 0.79，流動比率為 1.46。該業務的 50 日移動平均價為 0.33 美元，200 天移動平均價為 0.58 美元。
Institutional Inflows and Outflows
機構流入和流出
Institutional investors have recently added to or reduced their stakes in the company. Prudential Financial Inc. acquired a new position in Lucira Health during the 2nd quarter worth approximately $32,000. Renaissance Technologies LLC purchased a new stake in shares of Lucira Health during the second quarter worth $78,000. BlackRock Inc. lifted its position in shares of Lucira Health by 18.8% during the first quarter. BlackRock Inc. now owns 51,468 shares of the company's stock worth $183,000 after acquiring an additional 8,131 shares in the last quarter. AlphaCentric Advisors LLC purchased a new stake in shares of Lucira Health during the third quarter worth $339,000. Finally, Vanguard Group Inc. raised its position in shares of Lucira Health by 23.4% in the first quarter. Vanguard Group Inc. now owns 631,767 shares of the company's stock worth $2,256,000 after buying an additional 119,929 shares in the last quarter. 57.02% of the stock is owned by institutional investors and hedge funds.
機構投資者最近增加或減少了他們在公司的股份。英國保誠金融有限公司於第二季度收購了盧西拉健康的新職位，價值約 32,000 美元。文藝復興技術有限責任公司在第二季度期間購買了 Lucira 健康股份的新股份，價值 78,000 美元。貝萊德公司在第一季度將其在盧西拉健康股份的地位上升了 18.8％。在上一季度額外收購 8,131 股股份後，貝萊德公司現在擁有該公司股票 51,468 股，價值 183,000 美元。Alphacentric 顧問有限責任公司在第三季度購買了盧西拉健康股份的新股份，價值 339,000 美元。最後，先鋒集團公司在第一季度上調了其在盧西拉健康股份的位置 23.4％。領航集團股份有限公司現在擁有該公司股票的 631,767 股，價值 2,256,000 美元，在上一季度額外購入 119,929 股。57.02% 的股票由機構投資者和對沖基金擁有。
About Lucira Health
關於露西拉健康
(Get Rating)
(取得評分)
Lucira Health, Inc, a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits.
Lucira Health, Inc 是一家醫療技術公司，專注於傳染病檢 test 劑盒的開發和商業化。它開發了一個生產分子測試服務的測試平台。該公司提供 LUCIRA COVID-19 一體化檢測套件，一套 COVID-19 test 套件；並開發出甲型和乙型流感病毒 test 套件。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Lucira Health (LHDX)
- After an Earnings Blowout, Is Ciena Stock a Buying Opportunity?
- Here's Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
- Meta Breaks Out Of A Base, Looks Like A Growth Stock Again
- The Bottom Is In For McCormick & Company
- Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
- 免費獲取有關露西拉健康（LHDX）的研究報告
- 盈利井噴後，Ciena 股票是一個購買機會嗎？
- 這就是為什麼維京療法在肥胖症藥物數據上漲了 50％ 以上的原因
- Meta 突破了基礎，看起來再次成長股
- 底部是在麥考密克 & 公司
- 沃爾格林靴子聯盟：藍籌，高收益周轉故事
Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with MarketBeat.com's FREE daily email newsletter.
接收盧西拉健康日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Lucira Health 及相關公司的最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。